InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 11/10/21
InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare CannabinoidGlobeNewsWire • 11/03/21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare CannabinoidsGlobeNewsWire • 10/13/21
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis BullosaGlobeNewsWire • 09/30/21
InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 09/24/21
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 09/24/21
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021GlobeNewsWire • 09/17/21
InMed Pharmaceuticals and BayMedica Participating in Tribe Public's Webinar "Accelerating The Commercialization of Rare Cannabinoids"GlobeNewsWire • 09/17/21
InMed Pharmaceuticals To Acquire BayMedica, Rare Cannabinoid Manufacturer, For ~$3.66MBenzinga • 09/13/21
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids.Benzinga • 09/13/21
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare CannabinoidsGlobeNewsWire • 09/13/21
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/09/21
InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8thPRNewsWire • 09/07/21
InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production Of Rare Cannabinoids At Pharmaceutical LevelsBenzinga • 08/25/21
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual ConferenceGlobeNewsWire • 08/12/21
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 07/02/21
InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare CannabinoidsGlobeNewsWire • 06/29/21
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale ProductionGlobeNewsWire • 06/17/21
InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/16/21